44 results about "Attention deficit hyperactivity disorder" patented technology

The invention relates to the technical field of attention deficit hyperactivity disorder detection, and discloses a device for detecting cognitive and developmental conditions of children with hyperactivity disorder, which comprises a handle, a head-mounted device, a bracelet, a hierarchical adaptive algorithm module, a multi-dimensional execution module and a data fusion and analysis module, a multi-mode sensing module is arranged in each of the handle, the head-mounted device and the bracelet; a motion capture unit, a high-sensitivity key array, a tactile feedback module and a wireless transmission module are integrated in the handle, and a wireless electroencephalogram acquisition module, a miniature near infrared spectrum module and an eye movement tracking module are integrated in the head-mounted device. According to the invention, through deep fusion of a multi-dimensional cognitive evaluation system and gamepad hardware, the device not only breaks through the limitation of the traditional neuropsychological test in methodology, but also realizes refined capture of ADHD heterogeneity characteristics in the technical level, and provides a hardware basis for establishing an objective and quantitative diagnostic tool with high ecological efficiency.

The invention relates to the field of medical image analysis and neuropsychiatric disease diagnosis, and particularly discloses a brain network typing diagnosis system and method for attention deficit hyperactivity disorder. Comprising a data acquisition and preprocessing module, a topological feature extraction module, a supervised manifold learning module, a network reconstruction and diagnosis module, a parameter optimization module and a result verification module, continuous homology analysis is performed on a brain region function connection matrix based on an algebraic topology theory, and a brain region topological feature matrix is generated; utilizing supervised manifold learning to map the brain region topological feature matrix to a Riemannian manifold, and calculating a brain region importance weight map based on ADHD phenotypic features as supervised signals; according to the method, the brain network is subjected to subtype specific reconstruction through the curvature flow theory of Riemannian geometry, the topological difference between different subtypes is calculated, accurate typing diagnosis of ADHD is achieved, and the diagnosis accuracy is improved by 15%-20%.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The present invention relates to a system and method for real-time screening of Attention Deficit Hyperactivity Disorder using electroencephalographic signals processed through a GPU-accelerated time-frequency inference architecture. The invention enables continuous acquisition of multi-channel electroencephalographic data, adaptive preprocessing for artifact suppression and signal stabilization, and parallel execution of time-frequency transformations to extract neurologically relevant features in real time. Extracted features are analyzed using an inference process configured to identify neurological patterns associated with Attention Deficit Hyperactivity Disorder, while continuous validation of signal quality and temporal consistency ensures diagnostic reliability. The system dynamically adapts analytical parameters based on evolving signal characteristics and regulates computational workload to achieve energy-efficient operation during prolonged monitoring. The invention provides a technically integrated, machine-implemented screening solution capable of delivering reliable, real-time neurological assessment suitable for clinical environments.

The present invention relates to an improved method for the preparation of optically pure (S)-biloxazine or a salt thereof. The (S)-biloxazine prepared according to the preparation method of the present invention can be selectively administered to prevent or treat attention deficit hyperactivity disorder (ADHD). Accordingly, the dosage of a drug can be reduced by half or more, and side effects can be reduced.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Kits and diagnostic apparatus include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

The application discloses a game adjusting method and device and a storage medium, and relates to the technical field of games, and can improve the exercise efficiency of attention deficit hyperactivity disorder.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The present technology relates to sensory apparatuses that are useful for individuals who need assistance with neurodevelopmental conditions such as autism spectrum disorder (ASD), sensory processing disorder (SPD), attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Such apparatuses can include a top cover connected to or integral with a top base plate, and a bottom cover connected to or integral with a bottom base plate, about which projections or wings having different visual or tactile properties, such as different textures, are rotatably attached. The present technology is also directed to systems and methods for the management of a neurodevelopmental condition.

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

The present invention belongs to the field of microorganisms, and more particularly, the present invention relates to the use of Lactobacillus sanfranciscensis in the prevention, diagnosis and / or treatment of attention deficit hyperactivity disorder, and a microbial preparation for the prevention and / or treatment of attention deficit hyperactivity disorder. Therefore, a further evidence is provided for the correlation between the intestinal microbiota and the ADHD, and a new candidate is also provided for the treatment of the ADHD.

A system for assessing an ADHD status of a subject comprising:(a) receiving circuitry configured to receive a measurement signal including measurements of a plurality of nasal respirations from a sensor configured to sense a nasal respiration of a subject;(b) optional determining circuitry configured to determine values of one or more nasal respiration parameter from said measurement signal;(c) evaluation circuitry configured to evaluate said subject, based on said values of one or more respiration parameter to provide an indication of ADHD status of said subject.

This invention discloses a system and method for identifying Attention Deficit Hyperactivity Disorder (ADHD), belonging to the technical field of ADHD. The system includes: a data processing module for preprocessing and feature extraction of acquired EEG data; a multi-source feature fusion mechanism followed by data augmentation strategies for the extracted raw feature data; a multi-source fusion feedback regulation network model, employing a CNN-GRU parallel modeling structure; a training module for training the model using augmented data, dynamically adjusting key hyperparameters based on performance feedback on the validation set; and a classification module for classifying test samples using the trained multi-source fusion feedback regulation network model and outputting the final identification result. This invention effectively improves the accuracy, robustness, and generalization performance of ADHD EEG identification.

To provide 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for treatment of depression and the like.SOLUTION: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of, e.g., depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are, e.g., 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present specification discloses the synthesis and characterization of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention.SELECTED DRAWING: None

The present application relates to a compound as shown in formula (I), stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, and preparation method and pharmaceutical composition. The compound is an NK-3 receptor antagonist, which can be used for preventing and / or treating depression, anxiety, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory disease, vomiting, preeclampsia, airway related disease, reproductive disorder, contraception and sex hormone dependent disease, gynecological disease related disease, menopausal syndrome related disease.

The present invention discloses a method and device system for assisting in identifying attention deficit hyperactivity disorder (ADHD) based on electrocardiogram (ECG) signals. The method comprises: (1) collecting and processing ECG data of a subject whose risk of developing ADHD is to be assessed; (2) performing deep feature extraction on the processed ECG data of the subject using a one-dimensional convolutional neural network; generating a classification heat map from the feature map of the convolutional neural network using Score-CAM, and extracting time domain, frequency domain, and local statistical features from the generated classification heat map; and (3) inputting the time domain, frequency domain, and local statistical features into a machine learning classifier for classification, thereby obtaining an assessment result of the subject's risk of developing ADHD. The present invention combines deep learning with multiple machine learning methods, not only improving classification performance but also providing rich feature interpretability.

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

New use of 1-amino-3,5-dimethyladamantane hydrochloride in treating or preventing cognitive impairment, reducing microglia in the cortex and hippocampus, reducing neuron loss in the cortex and hippocampus, and ameliorating the mitochondrial dysfunction state. The cognitive impairment includes cognitive impairment in systemic lupus erythematosus, Parkinson's disease, lateral sclerosis, stroke, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, attention deficit hyperactivity disorder, sepsis-related encephalopathy, or mild cognitive disorder. The present application also provides a corresponding drug and a treatment or prevention method.

Provided herein are methods of treating attention deficit hyperactivity disorder using a KDM1A inhibitor, in particular vafenipristal.

Presented herein are methods of treating attention deficit hyperactivity disorder (ADHD), methods of treating depression, methods of treating an anxiety disorder, and methods of ameliorating cognitive impairment associated with a disorder or disease such as neurodegenerative disorders, ADHD, and schizophrenia, each comprising administering to a subject pharmaceutical compositions comprising an organic solvent-aqueous extract of Garcinia kola seeds. Also disclosed are methods of producing an organic solvent-aqueous extract of Garcinia kola seeds.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The present invention relates to methods and pharmaceutical compositions effective for treating, inhibiting, alleviating, slowing or delaying the onset of a mental disease in a mammal, such as a human, by administering an effective amount of a compound selected from Formula (I), Formula (II), Formula (III) or Formula (IV) or a pharmaceutically acceptable salt thereof. In certain embodiments, the present invention relates to methods and pharmaceutical compositions of an effective amount of a compound selected from the group consisting of Formula (I), Formula (II), Formula (III), or Formula (IV), or a pharmaceutically acceptable salt thereof, and an effective amount of an antipsychotic agent, an antidepressant agent, a magical agent, and combinations thereof. In certain embodiments, the mental disorder is autism, attention deficit hyperactivity disorder, bipolar affective disorder, severe depressive disorder, or schizophrenia.

This application provides a response testing system for Attention Deficit Hyperactivity Disorder (ADHD). The system comprises multiple cognitive response experiments, all designed and optimized based on cognitive psychology and cognitive neuroscience data, providing a comprehensive assessment of the subject. During the experiments, EEG data is collected from the subject. Based on this data, the frequency bands of interest in the response experiments are processed, and the data transformation and feature extraction are fed into a Multi-Stream Dual-Line Decision Neural Network (MSDD) model. This model selects different learning schemes based on different data types, learning the EEG data features and comparing their similarity to healthy norms, thereby achieving the purpose of assisting diagnosis.

1. The name of the design product: detection bin. 2. The use of the design product: detection bin for autism and attention deficit hyperactivity disorder detection and auxiliary diagnosis of children. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The present disclosure relates to the use of inositol-stabilized arginine (“ASI”) for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Some embodiments include the use of ASI for improving mental focus and / or attention span. For example, in some implementations, methods include administering an amount of ASI effective to improve mental focus and / or attention span in humans. Some embodiments include the use of ASI for treating and / or preventing cognitive disorders. Cognitive disorders may include stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss, attention deficit hyperactivity disorder (“ADHD”), and other learning disabilities.

The application discloses a VR training system based on the cognitive function defect characteristics of children's attention deficit hyperactivity disorder, relates to the technical field of digital medical treatment, and comprises a data acquisition module, a data evaluation module, a VR training module, a dynamic adjustment module, a result output module and a collaborative work module; the application constructs an objective quantitative model by fusing multi-modal data, accurately identifies three ADHD subtypes and the degree of cognitive defect of each dimension, solves the problem that traditional evaluation is highly subjective, and divides cold / hot executive function double-path training based on the CAPS theory, dynamically customizes task matching according to the subtypes, realizes accurate matching of defects and training, additionally, through real-time monitoring of eye movement and physiological indexes, automatically adjusts task difficulty and feedback strategies, maintains the best challenge level, can effectively improve the participation and training continuity of children, and finally achieves the goal of high-efficiency, high-interest and side-effect-free personalized digital therapy.